Bayer Schering Pharma is one of the world’s leading, innovative companies in the healthcare and medical products industry. Bayer Schering Pharma’s oncology business unit includes a global group of dedicated individuals working to develop solutions that improve the lives of cancer patients.
Through compassion and collaboration, Bayer continues to discover new treatments to help improve the health of cancer patients worldwide. Bayer Schering Pharma’s research efforts have resulted in a balanced, diverse portfolio of potential cancer therapies. The Company is proud to contribute to liver cancer research, development and education through support of the International Liver Cancer Association.
Novartis Oncology delivers a broad range of innovative therapies aimed at improving and extending the lives of patients. These include Glivec® (imatinib), Tasigna® (nilotinib), Exjade® (deferasirox), Zometa® (zoledronic acid), Sandostatin® LAR® (octreotide/IM injection) and Femara® (letrozole). Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.